Hood, 2007 |
SPIRO 50-100mg |
Crossover, 51 |
59.5±11.9 |
54 |
10 |
pmol/L |
375 (276-438) |
1116 (893-1339) |
4 (3.9-4.1) |
4.5
(4.4-4.6) |
Hood, 2007* |
AMIL 20-40mg |
Crossover, 51 |
59.5±11.9 |
54 |
10 |
pmol/L |
375 (276-438) |
963 (797-1129) |
4 (3.9-4.1) |
4.8
(4.6-4.9) |
Hood, 2007* |
BENDRO 2.5-5mg |
Crossover, 51 |
59.5±11.9 |
54 |
10 |
pmol/L |
375 (276-438) |
374 (330-419) |
4 (3.9-4.1) |
3.6
(3.4-3.8) |
Ubaid-Girioli, 2009 |
SPIRO 25mg |
Parallel, 39 |
… |
… |
24 |
ng/mL |
15.4±8.2 |
19.2±9 |
4.2±0.4 |
4.4±0.5 |
Ubaid-Girioli, 2009* |
SPIRO 25mg |
Parallel, 32 |
… |
… |
24 |
ng/mL |
16.8±5.4 |
22.3±12.6 |
4.1±0.3 |
4.3±0.4 |
Marone, 1985 |
CLTD 25-50mg |
Single-arm, 10 |
56.7±2.5 (SEM) |
40 |
6-8
weeks |
ng/dL |
6.98±0.79 |
11.91±2.93 |
4.5±0.2 |
4.5±0.4 |
Weinberger, 2002 |
E 50mg |
Parallel, 49 |
… |
70 |
8 |
ng/dL |
Mean-adjusted changes |
Mean-adjusted changes |
4.26 |
… |
Weinberger, 2002* |
E 100mg |
Parallel, 43 |
… |
61 |
8 |
ng/dL |
” |
” |
4.17 |
… |
Weinberger, 2002* |
E 400mg |
Parallel, 52 |
… |
64 |
8 |
ng/dL |
” |
” |
4.2 |
… |
Weinberger, 2002* |
E 25mg BD |
Parallel, 51 |
… |
73 |
8 |
ng/dL |
” |
” |
4.18 |
… |
Weinberger, 2002* |
E 50mg BD |
Parallel, 49 |
… |
70 |
8 |
ng/dL |
” |
” |
4.22 |
… |
Weinberger, 2002* |
E 200mg BD |
Parallel, 43 |
… |
69 |
8 |
ng/dL |
” |
” |
4.20 |
… |
Weinberger, 2002* |
SPIRO 50mgBD |
Parallel, 42 |
… |
75 |
8 |
ng/dL |
” |
” |
4.24 |
… |
Weinberger, 2002* |
Placebo |
Parallel, 49 |
… |
58 |
8 |
ng/dL |
” |
” |
4.2 |
… |
Karns, 2012 |
E 50mg BD |
Parallel, 33 |
56.2±7.7 |
57.6 |
8 |
… |
% change reported |
% change reported |
… |
… |
Karns, 2012* |
Placebo |
Parallel, 33 |
59.8±9.33 |
66.7 |
8 |
… |
” |
” |
… |
… |
Vasavada, 2003 |
TORS 40mg or FURO 80mg |
Crossover, 14 |
67 ± 11 |
93 |
3 |
ng/mL |
7.46±2.14 |
10.38±2.14 (w1), 11.47±1.84 (w3) |
… |
… |
Matsui, 2010 |
HCTZ 12.5mg |
Parallel, 104 |
68 ± 9.1 |
40 |
24 |
pg/mL |
37 (32.2-42.5) |
46.14 (est from % change) |
… |
… |
Lijnen, 1981 |
HCTZ 100mg |
Parallel, 5 |
37.2 ± 2.7 |
57.1 |
12 |
ng% |
4.28±1.48 [SE] |
8.11±1.31 |
4.12±0.15 |
3.44±0.22 |
Lijnen, 1981* |
TIE 250mg |
Parallel, 5 |
37.2 ± 2.7 |
57.1 |
12 |
ng% |
4.78±1.25 |
5.15±1.2 |
4.07±0.12 |
3.68±0.14 |
Lijnen, 1981* |
TIE 1000mg |
Parallel, 4 |
37.2 ± 2.7 |
57.1 |
12 |
ng% |
2.72±1.5 |
14.92±1.18 |
4.08±0.12 |
3.23±0.16 |
Koenig, 1991 |
HCTZ 25mg |
Crossover, 51 |
68±8 |
20 |
12 & 24 |
pg/mL |
70.4±30.6 |
91.5±42 (3m), 78.9±31 (6m) |
4.2±0.4 |
4.5±0.4 (3m),
4.3±0.4 (6m) |
Saruta, 2004 |
Placebo |
Parallel, 48 |
54.3±10.55 |
68 |
8 |
… |
% change reported |
% change reported |
… |
… |
Saruta, 2004* |
E50mg |
Parallel, 48 |
54.2±11.3 |
63.3 |
8 |
… |
% change reported |
% change reported |
… |
… |
Saruta, 2004* |
E100mg |
Parallel, 45 |
52.8±10.02 |
69.6 |
8 |
… |
% change reported |
% change reported |
… |
… |
Saruta, 2004* |
E200mg |
Parallel, 47 |
52.6±10.76 |
72.9 |
8 |
… |
% change reported |
% change reported |
… |
… |
Chalmers, 1982 |
INDA 2.5mg |
Crossover, 16 |
53±10 |
44 |
8 |
ng/100mL |
8 (placebo) |
13.8 (INDA) |
4.4 (placebo) |
3.6 (INDA) |
Calhoun, 2011 |
E 50mg BD |
Parallel, 68 |
55.3±9.1 |
59.7 |
8 |
pmol/L |
189.7 |
379.8 |
… |
… |
Calhoun, 2011* |
Placebo |
Parallel, 60 |
53.9±8.7 |
66.7 |
8 |
pmol/L |
181.7 |
172.3 |
… |
… |
Svendsen, 1983 |
HCTZ+AMIL |
Parallel, 15 |
48.5 |
43 |
12 |
pmol/L |
208 |
478.4 |
3.3 |
3.80 (est from %) |
Ubaid-Girioli, 2007 |
HCTZ 25mg |
Parallel, 18 |
49.3±7.2 |
46 |
12 |
ng/dL |
9.1±2.2 |
14.1±1.4 |
… |
… |
Ramsay 1981 |
Spiro 25mg |
Crossover, 14 |
50 |
43 |
4 |
pmol/L |
12.02±1.70 |
15.85±2.45 |
3±0.43 |
3.37±0.44 |
Ramsay 1981* |
SPIRO 50mg |
Crossover, 14 |
50 |
43 |
4 |
pmol/L |
12.02±1.70 |
31.62±1.41 |
3±0.43 |
3.52±0.48 |
Ramsay 1981* |
SPIRO 100mg |
Crossover, 14 |
50 |
43 |
4 |
pmol/L |
12.02±1.70 |
34.67±1.32 |
3±0.43 |
3.83±0.43 |
Ramsay 1981* |
SPIRO 200mg |
Crossover, 14 |
50 |
43 |
4 |
pmol/L |
12.02±1.70 |
42.66±1.78 |
3±0.43 |
3.91±0.35 |
Brummelen, 1979 |
HCTZ 50mg BD |
Single-arm, 13 |
26-58 |
100 |
1, 4,
12, 24, 36 |
ng/100mL |
5.7±0.9 [SE] |
8.5±0.6 (1w), 8.9±0.5 (4w),
8.7±0.6 (12w), 6.7±0.7 (24w), 6.8±0.8 (36w) |
4±0.04 |
3±0.1 (1W),
3.1±0.1 (4W), 3±0.1 (12w), 3.2±0.1 (24w), 3.2±0.1 (36w) |
O’Connor, 1980 |
HCTZ |
Crossover, 19 |
50.1 ± 2.6 |
100 |
4 |
pg/mL |
48.3±8 [SE] |
98.4±19 |
4.1±0.1 |
3.8±0.1 |
Ferguson, 1982 |
HCTZ 50mg |
Crossover, 4 |
51 |
66 |
2 |
ng/dL |
13.5
(Group 1), 11.6 (Group 2) |
21.8 (Group 1), 20.8 (group 2) |
… |
… |
Matthesen, 2012 |
AMIL 5mg BD |
Crossover, 23 |
60 (45-70) |
60.9 |
4 |
pmol/L |
84 (placebo) |
303 |
… |
… |
Matthesen, 2012* |
SPIRO 25mg BD |
Crossover, 23 |
60 (45-70) |
60.9 |
4 |
pmol/L |
84 (placebo) |
299 |
… |
… |
Ni, 2014 |
SPIRO 25mg |
Parallel, 40 |
55.7±12.3 |
60 |
12 |
pg/mL |
23.8±10.9 |
24.5±11 |
4.1±1.5 |
4.4±0.7 |
Ni, 2014* |
Placebo |
Parallel, 36 |
54.9±14.2 |
58.3 |
12 |
pg/mL |
23.4±10.2 |
23.5±9.8 |
3.9±0.9 |
4.1±1.4 |
Koopmans, 1987 |
HCTZ 50mg OD |
Crossover, 9 |
50.5±9.1 |
55.6 |
4 |
ng/100mL |
8.5±4.8 |
11.8±5.2 |
3.8±0.17 |
3.2±0.26 |
Swaminathan, 2008 |
SPIRO 25-50mg |
Crossover, 33 |
62.6 |
… |
4 |
pmol/L |
150.84±83.1 (placebo) |
264.33±107.81 |
4.4±0.3 |
4.8±0.37 |
Kreeft, 1983 |
CLTD 100mg |
Crossover, 19 |
42-66 |
52.6 |
8 |
ng/L |
7.8±4.8 |
11.56±10.9 |
4.31±0.4 |
3.35±0.3 |
Kreeft, 1983* |
SPIRO 400mg |
Crossover, 19 |
42-66 |
52.6 |
8 |
ng/L |
7.8±4.8 |
14.4±13.3 |
4.31±0.4 |
5±0.6 |
Jarvis, 2015 |
HCTZ 12.5-25mg |
Parallel, 10 |
68±6 |
50 |
24 |
ng/dL |
5.4±4.7 |
11.8±10.5* |
… |
… |
Yang, 2016 |
SPIRO 20-40mg |
Parallel, 15 |
44.7±10.8 |
… |
12 |
ng/dL |
18±5.4 |
8.2±3.3 |
4.3±0.3 |
4.3±0.2 |
Karashima, 2016 |
HCTZ 6.25mg |
Parallel, 22 |
65 ± 1 |
68 |
48 |
pg/mL |
87±6 (SEM) |
83±5 |
4.1±0.1 |
4.1±0.1 |
Karashima, 2016* |
E 50mg |
Parallel, 23 |
66 ± 2 |
68 |
48 |
pg/mL |
85±7 |
103±1* |
4.2±0.1 |
4.3±0.1 |
Karashima, 2016 |
SPIRO 12.5-100mg |
Parallel, 27 |
56.1±9.9 |
40.7 |
48 |
pg/mL |
128±55 |
244±84 |
3.9±0.3 |
4.3±0.3 |
Karashima, 2016* |
EPLER 25-100mg |
Parallel, 27 |
54.9±10.7 |
48.1 |
48 |
pg/mL |
140±60 |
184±88 |
3.9±0.3 |
4.2±0.3 |
Ferrara, 1988 |
CLTD 25mg |
Parallel,16 |
49±8 |
50 |
6 |
pg/mL |
222±105 |
320±227 |
… |
… |
Ferrara, 1988* |
Placebo |
Parallel, 16 |
49±8 |
50 |
6 |
pg/mL |
327±185 |
356±166 |
… |
… |
Derosa, 2018 |
CAN 50-100mg |
Parallel, 81 |
53.4 ± 7.2 |
53.4 |
24 &
48 |
pg/dL |
143.1 ± 22.5 |
121.8 ± 16.5 (6m), 104.6 ± 13.2 (12m) |
3.9
± 0.4 |
4.1 ± 0.6 (6m), 4.3 ± 0.7 (12m) |
Derosa, 2018* |
HCTZ 12.5-25mg |
Parallel, 82 |
52.6 ± 6.9 |
48.8 |
24
& 48 |
pg/dL |
153.8 ± 25.6 |
164.1 ± 27.9 (6m), 169.4 ± 30.6 (12m) |
4.1 ± 0.5 |
3.8 ± 0.4 (6m), 3.5 ± 0.3* (12m) |
Henning, 1980 |
AMIL+HCTZ |
Crossover, 43 |
… |
56.4 |
8 |
pmol/L |
416 |
1257 |
4.26 |
3.82 |
Krum, 2002 |
Placebo (added to ACE) |
Parallel, 60 |
54.7 |
51 |
8 |
ng/dL |
6.9 |
6.7 |
4.36 |
+0.06±0.04 |
Krum, 2002* |
Placebo (Added to ARB) |
Parallel, 58 |
55.1 |
40 |
8 |
ng/dL |
7.4 |
6.9 |
4.28 |
+0.05±0.03 |
Krum, 2002* |
EPLER 50-100mg (+ ACE) |
Parallel, 63 |
55.7 |
47 |
8 |
ng/dL |
7.1 |
11.8 |
4.32 |
+0.14±0.04 |
Krum, 2002* |
EPLER 50-100mg (+ ARB) |
Parallel,64 |
54.2 |
49 |
8 |
ng/dL |
7.8 |
12.4 |
4.31 |
+0.20±0.04 |
Derosa, 2016 |
CAN 50mg |
Parallel, 87 |
57.15±8.91 |
65.5 |
12 |
pg/dL |
58.64±54.67 |
77.76±72.14 |
4.25±0.43 |
4.50±0.45 |
Derosa, 2016* |
CAN 100mg |
Parallel, 88 |
57.75±9.18 |
63.6 |
12 |
pg/dL |
68.77±63.19 |
68.50±66.01 |
4.32±0.72 |
4.65±0.40 |
Belleau, 1982 |
HCTZ 50mg |
Crossover, 18 |
44 (23-58) |
54.6 |
4 |
ng/100mL |
10.99±5.6 |
10.90±4.84 |
… |
… |
Gerber, 1985 |
INDA 2.5mg |
One-arm, 29 |
37 ± 2 |
100 |
7.7 |
ng/dL |
8.2±0.8 (SEM) |
13.8±1.2 |
4.2±0.1 |
3.6±0.1 |
Fouassier, 2020 |
SPIRO+FUR+AMIL |
Parallel, 73 |
53.7 ± 10.3 |
79 |
12 |
pmol/L |
104 (69-152) Median+IQR |
270 (177-344) |
3.8±0.4 |
4.3±0.5 |
Dorresteijn, 2013 |
HCTZ 25mg |
Crossover, 29 |
60 (55–63) |
74 |
8 |
ng/L |
Placebo: 53 (33–74) Median IQR |
87 |
4.1 (4-4.5) |
3.82 |
Parthasarathy, 2011 |
SPIRO 75-225mg |
Parallel, 61 |
53.2±10.92 |
73.2 |
4 & 16 |
ng/dL |
20.1 |
37.7 (4w), 44.1 (16w) |
… |
3.93 (w4),
3.95 (w16) |
Parthasarathy, 2011* |
E 100-300mg |
Parallel, 67 |
53.9±10.89 |
62.9 |
4 & 16 |
ng/dL |
18.6 |
26.4 (4w), 33.3 (16w) |
… |
3.84 (w4),
3.95 (w6) |
Solini, 2019 |
HCTZ 12.5mg |
Parallel, 20 |
62±8 |
70 |
4 |
pg/mL |
1.44±0.95 |
1.01±0.43 |
4.57±0.35 |
4.47±0.31 |
Ohta, 2015 |
EPLER 50mg |
Crossover, 20 |
71 ±13 |
55 |
12 |
ng/dL |
15.4 ±8.0 |
21.0±11.8 |
4.3 ±0.5 |
4.8 ± 0.4 |
Ohta, 2015* |
INDA 1mg |
Crossover, 20 |
71 ±13 |
55 |
12 |
ng/dL |
15.4
±8.0 |
20.2±9.3 |
4.3 ±0.5 |
4.2 ± 0.4 |
Vaclavik, 2014 |
Placebo |
Parallel, 76 |
59.7±9.9 |
63.2 |
8 |
ng/L |
117 |
111 |
4.1±0.5 |
+0 |
Vaclavik, 2014 |
SPIRO 25mg |
Parallel, 74 |
60.4±9.5 |
67.6 |
8 |
ng/L |
87 |
143 |
4.1±0.5 |
+0.4 |
Kithas, 2010 |
HCTZ |
Parallel, 21 |
69 ± 6 |
52.4 |
24 |
ng/dL |
106 ±
49 |
157 ± 9 |
3.8 ± 0.4 |
3.8 ± 0.4 |
Kithas, 2010* |
SPIRO |
Parallel, 24 |
70 ± 5 |
58.3 |
24 |
ng/dL |
107
± 51 |
300 ± 37 |
4.1 ± 0.2 |
4.2 ± 0.3 |
Grandi, 2002 |
CAN 50mg |
Parallel, 17 |
… |
… |
24 |
pmol/L |
212.7±31.3 |
234.6±37.3* |
4.2±0.1 |
4.3±0.2 |
Olshan, 1981 |
FURO 40mg |
Crossover, 12 |
51.6±2.7 |
100 |
4 |
pg/mL |
Placebo: 66.1±9 (Supine) |
85.4±18.4 |
… |
… |
Meier, 1982 |
CLTD 100mg/day (responders) |
Parallel, 11 |
45±5 |
80 |
6 |
ng/100mL |
6.1±1.3 (Supine) |
12.5±3.1 & 39±15.2 |
4.0±0.1 |
3.4±0.1 |
Meier, 1982* |
CLTD 100mg/day (non-responders) |
Parallel, 9 |
54±3 |
80 |
6 |
ng/100mL |
4.1±0.9 (Supine) |
9.1±3.4 & 22.8±5.9 |
3.8± 0.1 |
3.1±0.2 |